Global Oncology Trends 2019 | RVX.TO Message Board Posts

Resverlogix Corp.

  RVX.TO website

  • Investor Village needs your help. We are working hard to improve your user experience
    by upgrading the site so it works better on the latest mobile devices, browsers, O/S, etc. Because costs exceed our normal operating budget, we are asking everyone, including "lurkers," to support our efforts.

    Click this PayPal link to make a one-time contribution in whatever amount you think is fair.

    Or click here to support us with a monthly contribution, starting as low as $2.50 per month.

    Payments can be made directly via PayPal or Credit Card with no need to create an Investor Village account. Cancel any time.

RVX.TO   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  27042 of 27059  at  5/31/2019 10:33:03 AM  by

rndtbl


Global Oncology Trends 2019

 
PD1/PD-L1 checkpoint inhibitors remain the most successful immuno-oncology therapies, and improvements in formulation (e.g., oral) or immunotherapy combinations with targeted therapies  


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 129
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board


About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...